VPH
-
Steve Saviuk of Valeo Pharma talks about acquiring new therapeutic drugs and record Q3 revenue
In this interview, InvestorIntel Publisher and Editor in Chief Stephen Lautens talks to Valeo Pharma Inc.’s (TSX: VPH…
-
Valeo Pharma’s Steve Saviuk talks about the US$40M non-dilutive financing from Sagard Healthcare Partners
In this InvestorIntel interview with host Tracy Weslosky, Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO and…
-
Steve Saviuk of Valeo Pharma on record 2021 revenues, achieving breakeven in 2022, and uplisting on the TSX
In a recent InvestorIntel interview, Tracy Weslosky spoke with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB:…
-
Revenue is forecast to triple, Valeo Pharma has 10 products in their portfolio
COVID-19 continues to be a huge global problem with global cases now over 112 million. Vaccines are a…
-
Valeo Pharma’s Steve Saviuk on Hesperidin and reducing the risk of securing COVID-19
In a new InvestorIntel interview Tracy Weslosky speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH…
-
Valeo Pharma on a significant upswing with recent Health Canada approvals
In a new InvestorIntel interview Peter Clausi speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH…